[Form 4] ZyVersa Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

CyberArk Software Ltd. (CYBR) has filed a Form 144 indicating a planned sale of 363 common shares acquired through restricted stock units on 15 Jan 2025. The anticipated transaction, to be executed through Morgan Stanley Smith Barney on the NASDAQ around 15 Jul 2025, carries an aggregate market value of US$136,861.89. With 49,426,711 shares outstanding, the proposed sale represents less than 0.001% of total shares, suggesting an immaterial effect on the public float. No other sales by the filer were reported in the past three months, and the filing contains the required representation that the seller is not aware of undisclosed material adverse information.

Insights

Securities Analyst

TL;DR: Routine Form 144 for 363 shares; negligible ownership impact, neutral signal.

The filing discloses an intended disposition worth roughly US$137k—minor relative to CyberArk’s US$10bn-plus market capitalisation and 49.4m shares outstanding. Such small-scale insider activity is typical for employee equity compensation and does not, by itself, imply a change in corporate outlook or insider sentiment. No pattern of recent selling is cited, and the Form 144 includes the standard certification of no undisclosed adverse information. Investors generally treat sales under 0.1% of float as non-material; therefore, I categorise this event as non-impactful.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Wolfe Peter

(Last) (First) (Middle)

C/O ZYVERSA THERAPEUTICS, INC.

2200 N. COMMERCE PARKWAY, SUITE 208

(Street)

WESTON FL 26333

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ZyVersa Therapeutics, Inc. [ ZVSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
07/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$0.59	07/11/2025		A		60,100		(1)	07/11/2035	Common Stock	60,100	$0	60,100	D

Explanation of Responses:

1. The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Stephen C. Glover as Attorney-in-Fact for Peter Wolfe pursuant to Power of Attorney	07/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CyberArk (CYBR) file with the SEC?

A Form 144 notice of proposed sale of restricted securities.

How many CYBR shares are planned for sale under this Form 144?

363 common shares are slated for disposition.

What is the approximate value of the shares to be sold?

The aggregate market value is US$136,861.89.

When is the anticipated sale date for the CYBR shares?

Approximately 15 July 2025.

What percentage of CyberArk’s outstanding shares does the sale represent?

Less than 0.001% of the 49,426,711 shares outstanding.